Atomo Diagnostics Limited
Atomo Diagnostics Limited (AT1.AX) Stock Competitors & Peer Comparison
See (AT1.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AT1.AX | A$0.04 | +0.00% | 32.4M | -4.00 | -A$0.01 | N/A |
| COH.AX | A$170.23 | +2.62% | 11.1B | 32.30 | A$5.27 | +2.53% |
| 4DX.AX | A$6.28 | +0.00% | 3.6B | -15.70 | -A$0.40 | N/A |
| PNV.AX | A$0.90 | +0.00% | 618.3M | 89.50 | A$0.01 | N/A |
| IMR.AX | A$1.92 | -2.54% | 477.8M | -17.41 | -A$0.11 | N/A |
| AVR.AX | A$7.90 | -1.86% | 290.6M | -2.16 | -A$3.65 | N/A |
| EBR.AX | A$0.64 | -1.54% | 288.2M | -3.76 | -A$0.17 | N/A |
| ARX.AX | A$0.57 | +0.00% | 196.9M | -57.00 | -A$0.01 | N/A |
| EMV.AX | A$1.55 | +0.00% | 144.1M | -12.92 | -A$0.12 | N/A |
| SOM.AX | A$0.65 | -0.77% | 141.3M | -64.50 | -A$0.01 | N/A |
Stock Comparison
AT1.AX vs COH.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, COH.AX has a market cap of 11.1B. Regarding current trading prices, AT1.AX is priced at A$0.04, while COH.AX trades at A$170.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas COH.AX's P/E ratio is 32.30. In terms of profitability, AT1.AX's ROE is -0.58%, compared to COH.AX's ROE of +0.18%. Regarding short-term risk, AT1.AX is more volatile compared to COH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check COH.AX's competition here
AT1.AX vs 4DX.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, 4DX.AX has a market cap of 3.6B. Regarding current trading prices, AT1.AX is priced at A$0.04, while 4DX.AX trades at A$6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas 4DX.AX's P/E ratio is -15.70. In terms of profitability, AT1.AX's ROE is -0.58%, compared to 4DX.AX's ROE of -8.91%. Regarding short-term risk, AT1.AX is less volatile compared to 4DX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AT1.AX.Check 4DX.AX's competition here
AT1.AX vs PNV.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, PNV.AX has a market cap of 618.3M. Regarding current trading prices, AT1.AX is priced at A$0.04, while PNV.AX trades at A$0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas PNV.AX's P/E ratio is 89.50. In terms of profitability, AT1.AX's ROE is -0.58%, compared to PNV.AX's ROE of +0.12%. Regarding short-term risk, AT1.AX is more volatile compared to PNV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check PNV.AX's competition here
AT1.AX vs IMR.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, IMR.AX has a market cap of 477.8M. Regarding current trading prices, AT1.AX is priced at A$0.04, while IMR.AX trades at A$1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas IMR.AX's P/E ratio is -17.41. In terms of profitability, AT1.AX's ROE is -0.58%, compared to IMR.AX's ROE of -1.10%. Regarding short-term risk, AT1.AX is more volatile compared to IMR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check IMR.AX's competition here
AT1.AX vs AVR.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, AVR.AX has a market cap of 290.6M. Regarding current trading prices, AT1.AX is priced at A$0.04, while AVR.AX trades at A$7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas AVR.AX's P/E ratio is -2.16. In terms of profitability, AT1.AX's ROE is -0.58%, compared to AVR.AX's ROE of -7.74%. Regarding short-term risk, AT1.AX is more volatile compared to AVR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check AVR.AX's competition here
AT1.AX vs EBR.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, EBR.AX has a market cap of 288.2M. Regarding current trading prices, AT1.AX is priced at A$0.04, while EBR.AX trades at A$0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas EBR.AX's P/E ratio is -3.76. In terms of profitability, AT1.AX's ROE is -0.58%, compared to EBR.AX's ROE of -1.52%. Regarding short-term risk, AT1.AX is more volatile compared to EBR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check EBR.AX's competition here
AT1.AX vs ARX.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, ARX.AX has a market cap of 196.9M. Regarding current trading prices, AT1.AX is priced at A$0.04, while ARX.AX trades at A$0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas ARX.AX's P/E ratio is -57.00. In terms of profitability, AT1.AX's ROE is -0.58%, compared to ARX.AX's ROE of -0.04%. Regarding short-term risk, AT1.AX is more volatile compared to ARX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check ARX.AX's competition here
AT1.AX vs EMV.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, EMV.AX has a market cap of 144.1M. Regarding current trading prices, AT1.AX is priced at A$0.04, while EMV.AX trades at A$1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas EMV.AX's P/E ratio is -12.92. In terms of profitability, AT1.AX's ROE is -0.58%, compared to EMV.AX's ROE of -0.70%. Regarding short-term risk, AT1.AX is more volatile compared to EMV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check EMV.AX's competition here
AT1.AX vs SOM.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, SOM.AX has a market cap of 141.3M. Regarding current trading prices, AT1.AX is priced at A$0.04, while SOM.AX trades at A$0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas SOM.AX's P/E ratio is -64.50. In terms of profitability, AT1.AX's ROE is -0.58%, compared to SOM.AX's ROE of -0.05%. Regarding short-term risk, AT1.AX is more volatile compared to SOM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check SOM.AX's competition here
AT1.AX vs AVH.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, AVH.AX has a market cap of 137.3M. Regarding current trading prices, AT1.AX is priced at A$0.04, while AVH.AX trades at A$1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas AVH.AX's P/E ratio is -2.21. In terms of profitability, AT1.AX's ROE is -0.58%, compared to AVH.AX's ROE of +4.78%. Regarding short-term risk, AT1.AX is more volatile compared to AVH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check AVH.AX's competition here
AT1.AX vs CYC.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, CYC.AX has a market cap of 90.6M. Regarding current trading prices, AT1.AX is priced at A$0.04, while CYC.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas CYC.AX's P/E ratio is -4.69. In terms of profitability, AT1.AX's ROE is -0.58%, compared to CYC.AX's ROE of -0.54%. Regarding short-term risk, AT1.AX is more volatile compared to CYC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check CYC.AX's competition here
AT1.AX vs CMP.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, CMP.AX has a market cap of 55.9M. Regarding current trading prices, AT1.AX is priced at A$0.04, while CMP.AX trades at A$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas CMP.AX's P/E ratio is -28.00. In terms of profitability, AT1.AX's ROE is -0.58%, compared to CMP.AX's ROE of +0.00%. Regarding short-term risk, AT1.AX is more volatile compared to CMP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check CMP.AX's competition here
AT1.AX vs RSH.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, RSH.AX has a market cap of 52M. Regarding current trading prices, AT1.AX is priced at A$0.04, while RSH.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas RSH.AX's P/E ratio is -3.30. In terms of profitability, AT1.AX's ROE is -0.58%, compared to RSH.AX's ROE of -4.12%. Regarding short-term risk, AT1.AX is more volatile compared to RSH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check RSH.AX's competition here
AT1.AX vs MX1.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, MX1.AX has a market cap of 39.9M. Regarding current trading prices, AT1.AX is priced at A$0.04, while MX1.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas MX1.AX's P/E ratio is -2.75. In terms of profitability, AT1.AX's ROE is -0.58%, compared to MX1.AX's ROE of -1.80%. Regarding short-term risk, AT1.AX is more volatile compared to MX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check MX1.AX's competition here
AT1.AX vs CSX.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, CSX.AX has a market cap of 38.2M. Regarding current trading prices, AT1.AX is priced at A$0.04, while CSX.AX trades at A$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas CSX.AX's P/E ratio is 23.25. In terms of profitability, AT1.AX's ROE is -0.58%, compared to CSX.AX's ROE of +0.09%. Regarding short-term risk, AT1.AX is more volatile compared to CSX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check CSX.AX's competition here
AT1.AX vs EYE.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, EYE.AX has a market cap of 37M. Regarding current trading prices, AT1.AX is priced at A$0.04, while EYE.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas EYE.AX's P/E ratio is -6.50. In terms of profitability, AT1.AX's ROE is -0.58%, compared to EYE.AX's ROE of -0.40%. Regarding short-term risk, AT1.AX is more volatile compared to EYE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check EYE.AX's competition here
AT1.AX vs HMD.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, HMD.AX has a market cap of 36.4M. Regarding current trading prices, AT1.AX is priced at A$0.04, while HMD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas HMD.AX's P/E ratio is -4.60. In terms of profitability, AT1.AX's ROE is -0.58%, compared to HMD.AX's ROE of -4.18%. Regarding short-term risk, AT1.AX is more volatile compared to HMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check HMD.AX's competition here
AT1.AX vs IPD.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, IPD.AX has a market cap of 30.6M. Regarding current trading prices, AT1.AX is priced at A$0.04, while IPD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas IPD.AX's P/E ratio is -1.50. In terms of profitability, AT1.AX's ROE is -0.58%, compared to IPD.AX's ROE of -1.65%. Regarding short-term risk, AT1.AX is more volatile compared to IPD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check IPD.AX's competition here
AT1.AX vs LBT.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, LBT.AX has a market cap of 29.9M. Regarding current trading prices, AT1.AX is priced at A$0.04, while LBT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas LBT.AX's P/E ratio is -0.42. In terms of profitability, AT1.AX's ROE is -0.58%, compared to LBT.AX's ROE of -3.23%. Regarding short-term risk, AT1.AX is more volatile compared to LBT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check LBT.AX's competition here
AT1.AX vs CDX.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, CDX.AX has a market cap of 19.8M. Regarding current trading prices, AT1.AX is priced at A$0.04, while CDX.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas CDX.AX's P/E ratio is -0.90. In terms of profitability, AT1.AX's ROE is -0.58%, compared to CDX.AX's ROE of -2.17%. Regarding short-term risk, AT1.AX is more volatile compared to CDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check CDX.AX's competition here
AT1.AX vs CBL.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, CBL.AX has a market cap of 17.9M. Regarding current trading prices, AT1.AX is priced at A$0.04, while CBL.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas CBL.AX's P/E ratio is -2.80. In terms of profitability, AT1.AX's ROE is -0.58%, compared to CBL.AX's ROE of -0.98%. Regarding short-term risk, AT1.AX is more volatile compared to CBL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check CBL.AX's competition here
AT1.AX vs NTI.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, NTI.AX has a market cap of 13.1M. Regarding current trading prices, AT1.AX is priced at A$0.04, while NTI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas NTI.AX's P/E ratio is -1.30. In terms of profitability, AT1.AX's ROE is -0.58%, compared to NTI.AX's ROE of -0.87%. Regarding short-term risk, AT1.AX is more volatile compared to NTI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check NTI.AX's competition here
AT1.AX vs RNO.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, RNO.AX has a market cap of 11.5M. Regarding current trading prices, AT1.AX is priced at A$0.04, while RNO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas RNO.AX's P/E ratio is -1.00. In terms of profitability, AT1.AX's ROE is -0.58%, compared to RNO.AX's ROE of +15.91%. Regarding short-term risk, AT1.AX is more volatile compared to RNO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check RNO.AX's competition here
AT1.AX vs TRU.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, TRU.AX has a market cap of 9.7M. Regarding current trading prices, AT1.AX is priced at A$0.04, while TRU.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas TRU.AX's P/E ratio is -1.30. In terms of profitability, AT1.AX's ROE is -0.58%, compared to TRU.AX's ROE of -1.13%. Regarding short-term risk, AT1.AX is more volatile compared to TRU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check TRU.AX's competition here
AT1.AX vs OSL.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, OSL.AX has a market cap of 9.7M. Regarding current trading prices, AT1.AX is priced at A$0.04, while OSL.AX trades at A$0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas OSL.AX's P/E ratio is -0.55. In terms of profitability, AT1.AX's ROE is -0.58%, compared to OSL.AX's ROE of -3.72%. Regarding short-term risk, AT1.AX is more volatile compared to OSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check OSL.AX's competition here
AT1.AX vs IRX.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, IRX.AX has a market cap of 6.9M. Regarding current trading prices, AT1.AX is priced at A$0.04, while IRX.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas IRX.AX's P/E ratio is -2.80. In terms of profitability, AT1.AX's ROE is -0.58%, compared to IRX.AX's ROE of +2.96%. Regarding short-term risk, AT1.AX is less volatile compared to IRX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AT1.AX.Check IRX.AX's competition here
AT1.AX vs OVN.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, OVN.AX has a market cap of 4.8M. Regarding current trading prices, AT1.AX is priced at A$0.04, while OVN.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas OVN.AX's P/E ratio is -0.40. In terms of profitability, AT1.AX's ROE is -0.58%, compared to OVN.AX's ROE of -0.80%. Regarding short-term risk, AT1.AX is more volatile compared to OVN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check OVN.AX's competition here
AT1.AX vs ALT.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, ALT.AX has a market cap of 4.6M. Regarding current trading prices, AT1.AX is priced at A$0.04, while ALT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas ALT.AX's P/E ratio is N/A. In terms of profitability, AT1.AX's ROE is -0.58%, compared to ALT.AX's ROE of -2.31%. Regarding short-term risk, AT1.AX is more volatile compared to ALT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check ALT.AX's competition here
AT1.AX vs UBI.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, UBI.AX has a market cap of 4.2M. Regarding current trading prices, AT1.AX is priced at A$0.04, while UBI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas UBI.AX's P/E ratio is -0.23. In terms of profitability, AT1.AX's ROE is -0.58%, compared to UBI.AX's ROE of -1.19%. Regarding short-term risk, AT1.AX is more volatile compared to UBI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check UBI.AX's competition here
AT1.AX vs ADR.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, ADR.AX has a market cap of 3.9M. Regarding current trading prices, AT1.AX is priced at A$0.04, while ADR.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas ADR.AX's P/E ratio is -0.20. In terms of profitability, AT1.AX's ROE is -0.58%, compared to ADR.AX's ROE of +4.60%. Regarding short-term risk, AT1.AX is less volatile compared to ADR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AT1.AX.Check ADR.AX's competition here
AT1.AX vs VTI.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, VTI.AX has a market cap of 3.7M. Regarding current trading prices, AT1.AX is priced at A$0.04, while VTI.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas VTI.AX's P/E ratio is -0.55. In terms of profitability, AT1.AX's ROE is -0.58%, compared to VTI.AX's ROE of -0.57%. Regarding short-term risk, AT1.AX is more volatile compared to VTI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check VTI.AX's competition here
AT1.AX vs AMT.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, AMT.AX has a market cap of 3.5M. Regarding current trading prices, AT1.AX is priced at A$0.04, while AMT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas AMT.AX's P/E ratio is -1.45. In terms of profitability, AT1.AX's ROE is -0.58%, compared to AMT.AX's ROE of -11.52%. Regarding short-term risk, AT1.AX is less volatile compared to AMT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AT1.AX.Check AMT.AX's competition here
AT1.AX vs UCM.AX Comparison April 2026
AT1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AT1.AX stands at 32.4M. In comparison, UCM.AX has a market cap of 3.1M. Regarding current trading prices, AT1.AX is priced at A$0.04, while UCM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AT1.AX currently has a P/E ratio of -4.00, whereas UCM.AX's P/E ratio is -0.60. In terms of profitability, AT1.AX's ROE is -0.58%, compared to UCM.AX's ROE of -3.58%. Regarding short-term risk, AT1.AX is more volatile compared to UCM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AT1.AX.Check UCM.AX's competition here